Conning Inc’s Cymabay Therapeutics CBAY Stock Holding History

Conning Inc’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-78,529	Closed	-$492K	–	382
2022 Q4	$492K	Buy	+78,529	New	+$298K	0.02%	237
2019 Q4	–	Sell	-78,529	Closed	-$402K	–	512
2019 Q3	$402K	Hold	78,529	–	–	0.01%	344
2019 Q2	$562K	Hold	78,529	–	–	0.02%	295
2019 Q1	$1.04M	Hold	78,529	–	–	0.03%	239
2018 Q4	$618K	Hold	78,529	–	–	0.02%	297
2018 Q3	$870K	Buy	+78,529	New	+$975K	0.03%	288

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Conning Inc's CBAY Position: Q1 2023 in Review

Conning Inc sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 78,529 shares — an estimated $492K sold.

Conning Inc first reported a position in CBAY in Q3 2018 and held it in 6 quarters. The position peaked at $1.04M in Q1 2019. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

Conning Inc reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
Conning Inc sold 78,529 Cymabay Therapeutics shares in Q1 2023, an estimated $492K.
Conning Inc first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 6 quarters.
Conning Inc's Cymabay Therapeutics position peaked at $1.04M in Q1 2019.
139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on Conning Inc's 13F filing for Q1 2023, filed 27 Apr 2023.